Tuesday, February 9, 2010

Stock Idea: Alembic Limited

Alembic Ltd— BUY—45—INR
Sector — Pharmaceuticals
Regd.Off.— Alembic Road, Vadodara, Gujarat -390003
Listed — NSE, BSE.
Company Overview—
Alembic started its operations on 30 July, 1907 & now it is Asia's most respected integrated pharmaceutical company with manufacturing facilities in Vadodara and Panelav in Gujarat and Baddi in Himachal Pradesh. The plant in Vadodara has the largest fermentation capacity in India. The Panelav facility houses both API (USFDA approved) and formulation manufacturing plants. It has a distribution network that spans 29 states in India and 75 countries globally. Company has "Bio Arc Research Center" at vadodara to capitalize its strength in research and developments. Alembic is a certified ISO-9002 and ISO-14001 company with manufacturing practices and facilities that conform to WHO-GMP guidelines ensuing that every Alembic product meets the most stringent quality standards. Alembic is spreading its wings now to regulatory markets both in respect of API and Formulation. Company’s extensive range of "Finished Dosage Forms" covers every aspect of human life. It has expertise in the manufacturing of high volume Finished Dosage Forms and effectively control their release profile. This expertise is in the field of sterile as well as non-sterile dosage forms. Research and Development at Alembic is focused on fermentation technology, strain improvement, industrial enzymes, non-infringing process developments for API & intermediates, development of innovative formulations, NDDS. Company’s research is mainly involved into Chemistry & synthesis, Formulations development and Contract research.
Products & Services—
Company manufactures pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. It also promotes herbal products. The major therapeutic segments where Alembic has presence are antibiotics and antibacterial, cough and cold remedies, analgesic and anti-inflammatory medications, nutraceuticals and anti-diabetics. Company’s business division includes Alembic Mainline Pharma division. It services general practitioners, physicians, ENT Surgeons, paediatricians and orthopaedics. Megacare division has greater focus towards gynaecologists, besides physicians, ENTs, Paediatricians and GPs. Specia division includes speciality brands for cardiovascular and diabetology.
In Branded formulations company manufactures Antibiotics & Anti bacterials, cough & cold, antihistamines, NSAIDS, oral hypoglycemic, herbals & nutraceuticals, cardiovascular, others. In Generics it have 90 brands with extension in various forms covering the therapeutic segments of Antibiotic, Cough & cold, NSAID, B-complex, C.V.Drugs etc. it covers Therapeutic segments, antiallergic, anticold preparation, antimalarials, antioxidants, antiseptic, antiulcerants, corticosterroids, enzyme preparation, Nsaids, antithelminitic, antimicrobials, antipyretics, antispasmodic, cardiovascular drugs, cough preparations, mucolytics & proteolytics, tranquiliser, vitamin preparations, others.
At CMP, Stock is trading at attractive valuation of 8.96 P/E multiple of its FY2011 estimated earnings. We recommend investors to Buy "Alembic limited" with medium to long-term investment horizon.
Source: Internet (valuenotes by Abhishek Jain)

No comments:


The information in this publication is provided by http://www.moneybazzar.blogspot.com/ is intended for use for Readers & Traders . Every effort is made to provide accurate information, but http://www.moneybazzar.blogspot.com/ cannot guarantee the accuracy of the information or of the market analysis. This is a newsletter and is for informational purposes only. It is not a solicitation or offer to buy or sell futures. There is a high risk of loss in trading futures. You should not trade with money that you cannot afford to lose. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this newsletter. The past performance of any trading system or methodology is not necessarily indicative of future results.

free counter